2021. november: A közelmúltban megkezdődött a dél-koreai új generációs kiméra antigénreceptor T (CAR-T) sejtterápia első klinikai vizsgálata, amelyet az immunellenőrző pontok megkerülésére terveztek.
A Koreai Fejlett Tudományos és Technológiai Intézet (KAIST) szerdán bejelentette, hogy a szöuli Samsung Medical Centerben jelenleg is zajlik a CAR-T sejtterápia 1b fázisú klinikai vizsgálata. A kísérletet 10 koreai beteggel végzik, akiknél relapszus és refrakter diffúz nagy B-sejtes limfóma van. A csővezeték marketingjogait az egyetem a Curocell céghez ruházta át, amelynek társalapítója Kim Chan-hyuk professzor volt. A Curocell felel a forradalmár klinikai fejlesztési programjáért immunterápia.
In addition, a Phase 2 klinikai vizsgálat involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for kiméra antigén receptor T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Érdemes elolvasni: CAR T-sejt terápia Koreában
A tanulmány eredményeit a Molecular Therapy októberi számában online közzétett cikkben mutatták be.
